Puma Biotechnology Inc. (PBYI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company's earnings call. Management attributed the quarter's product revenue performance in part to a specialty pharmacy and distributor inventory drawdown and highlighted new interim clinical data from ongoing Phase II alisertib studies in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer.
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $0.1 per share a year ago.
Gun Makers Reach Cooperation Pact After Months of Tense Proxy Battle
Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to 25% of outstanding shares, including a tender offer at a minimum of $44.80 a share.
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Puma Biotechnology: Step By Step In Making A Transition
Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.45 per share a year ago.
